Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk (NVO) stock jumped 12% in pre-market ... that the pill could lead to more and faster weight loss than popular weekly injection Wegovy. Novo Nordisk said that patients that took ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug. The maker of Ozempic and Wegovy said ...

Novo Nordisk's stock ... company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's blockbuster weight-loss and diabetes drugs Wegovy ...

Also Read: Popular Ozempic, Wegovy ... superior weight loss of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4 mg and 2.4% with placebo. Price Action: NVO stock is ...

Many people on these weight-loss drugs - which include Ozempic, Wegovy, Zepbound and Mounjaro ... even though some have faced declines in their stock prices at times attributable to such concerns.